Dataset Information


MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with less than 5% of patients surviving 5 years beyond diagnosis. Systemic therapies, particularly gemcitabine, have a modest clinical benefit, but chemoresistance limits their efficacy. Here, we demonstrate that plasma miR-33a levels positively correlated with miR-33a levels in tumor tissues of patients with PDAC and are a good prognostic indicator of overall survival. Overexpression of miR-33a inhibited tumor cell proliferation and increased the chemosensitivity to gemcitabine both in vitro and in vivo. Moreover, miR-33a targets Pim-3 directly in PDAC. Pim-3 expression was a prognostic indicator related to poor survival in pancreatic cancer patients. Plasma miR-33a levels were significantly lower in pancreatic cancer patients with high Pim-3 protein expression than in healthy controls. Furthermore, overexpression of miR-33a in pancreatic cancer cell lines suppressed Pim-3 expression, leading to downregulation of the AKT/Gsk-3?/?-catenin pathway. Overall, these results indicate that miR-33a functions as a tumor suppressor that downregulates Pim-3 kinase expression to inhibit both pancreatic tumor growth and gemcitabine resistance via the AKT/?-catenin pathway. Hence, detection of plasma miR-33a may be a simple and convenient method of predicting therapeutic responses.


PROVIDER: S-EPMC4546478 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5746084 | BioStudies
2019-01-01 | S-EPMC6602779 | BioStudies
2019-01-01 | S-EPMC6775620 | BioStudies
2019-01-01 | S-EPMC6525710 | BioStudies
2015-01-01 | S-EPMC4452412 | BioStudies
2020-01-01 | S-EPMC6921186 | BioStudies
2014-01-01 | S-EPMC4153643 | BioStudies
2018-01-01 | S-EPMC5923350 | BioStudies
2014-01-01 | S-EPMC4202147 | BioStudies
1000-01-01 | S-EPMC5883523 | BioStudies